bioRxiv Science⌕ Search

bioRxiv · 10.1101/2025.01.24.634648

From Toxicogenomics Data to Cumulative Assessment Groups: A Mechanistic Framework for Chemical Grouping

Abstract

The grouping of chemicals based on shared properties or molecular mechanisms of action is pivotal for advancing regulatory toxicology, reducing data gaps, and enabling cumulative risk assessments. This study introduces a novel framework usingChemical-Gene-Phenotype-Disease (CGPD) tetramers derived from the Comparative Toxicogenomics Database (CTDbase). Our approach integrates toxicogenomics data to identify and cluster chemicals with similar molecular and phenotypic effects across diverse categories, including pesticides, pharmaceuticals, and industrial chemicals such as bisphenols and per- and poly-fluoroalkyl substances (PFAS). We validated our method by comparing CGPD Tetramer-based clusters with cumulative assessment groups (CAGs) for pesticides, demonstrating strong overlap with established groupings while identifying additional compounds relevant for risk assessment. Key examples include clusters associated with endocrine disruption and metabolic disorders.By bridging omics-derived molecular data with phenotypic and disease endpoints, this framework provides a comprehensive tool for chemical grouping and supports evidence-based regulatory decision-making, facilitating the transition to next-generation risk assessment methodologies.

Explore related subjects

Keep this discovery

Explore connections, maps & timelines

BibTeXRIS

Canzler, S., Lehmann, J., Schor, J., Busch, W., Hackermuller, J.. 2025-01-26. From Toxicogenomics Data to Cumulative Assessment Groups: A Mechanistic Framework for Chemical Grouping. https://doi.org/10.1101/2025.01.24.634648

Cite the original work for its findings. Save a collection to share your selection of sources.

KEEP EXPLORING

Related preprints

Lipid-ASO therapeutics exhibit differential tissue targeted delivery upon systemic or local CNS administration

Antisense oligonucleotides (ASOs) are a powerful therapeutic modality, but their full potential is hindered by pharmacokinetic properties that affect tissue and cellular delivery. Lipid conjugation is increasingly used to modulate ASO's biodistribution and promote extrahepatic activity, yet lipid dependent effects on in vivo functional delivery, particularly in the central nervous system (CNS), remain less explored. Here, we performed a side by side in vivo comparison of cholesterol, palmitic acid (C16:0), docosanoic acid (C22:0), and eicosapentaenoic acid (C20:5) conjugated to a fully phosphorothioated 3 10 3 LNA gapmer ASO targeting the Malat1 long non coding RNA. Lipid-ASO conjugates were administered systemically or locally in the brain of mice and evaluated for tissue level and cellular level distribution by imaging, qPCR and single-cell RNA sequencing, simultaneously annotating cell origin and global transcriptional changes within the cell. Following systemic administration in mice, lipid conjugation improved overall multi organ efficacy compared to unconjugated ASO, but with pronounced tissue specific differences. Single cell sequencing of liver and heart transcriptomes revealed lipid dependent cellular uptake patterns and transcriptional responses distinct from administration of unconjugated ASO. After intracerebroventricular administration, selected fatty acid conjugates enhanced silencing in deep brain regions such as the striatum, whereas cholesterol conjugation impaired functional delivery despite increased CNS retention. Light-sheet microscopy showed restricted parenchymal penetration of cholesterol ASOs compared with broader but heterogeneous distribution of palmitic acid conjugate. Together, these findings demonstrate that lipid identity critically determines ASO efficacy, productive cellular uptake, and regional CNS engagement, emphasizing the need for context specific lipid design in ASO therapeutic development.

pharmacology and toxicology↗

Novel Dissymmetric Ionizable Lipid-Assembled Lipid Nanoparticles for Delivery of Ferroptosis-Related siRNA in Diabetic Treatment

Small interfering RNA (siRNA) enables precise post-transcriptional gene silencing for refractory diseases, yet its clinical translation remains limited by the lack of safe and efficient delivery vectors. Inspired by the dissymmetric alkyl chain architecture of natural membrane phospholipids, we designed and synthesized 34 novel ionizable lipids with dissymmetric hydrophobic tails and formulated them into lipid nanoparticles (LNPs). Through systematic physicochemical and biological assessments, we established clear structure-activity relationships and identified two lead LNPs (O14-LNP, H18a-LNP) with superior endosomal escape capacity, enhanced in vivo gene silencing potency, and favorable biosafety relative to the clinical benchmark MC3-LNP. In both streptozotocin-induced and spontaneous db/db type 2 diabetes (T2D) mouse models, lead LNPs delivering ferroptosis-related siRNAs effectively ameliorated glucose and lipid metabolic disorders, restored islet function, and alleviated hepatic steatosis. This study not only lays a theoretical foundation for the rational design of novel ionizable lipids, but also validates the therapeutic potential of siRNA therapy targeting ferroptosis, providing a versatile delivery platform and targeted therapeutic strategy for the treatment of T2D.

pharmacology and toxicology↗

Effects of commercial unflavored and vanilla-flavored e-liquids on nicotine intake and withdrawal

Electronic cigarette liquids (e-liquids) often contain flavors and solvents that may influence nicotine addiction. In this study, we characterized the dose-response relationship of commercial unflavored nicotine e-liquids and investigated the impact of vanilla-flavored e-liquids on nicotine vapor self-administration (VSA) and withdrawal in rats. Male adolescent Sprague Dawley rats self-administered aerosols generated from commercial e-liquids containing 0, 3, 6, or 12 mg/ml nicotine in a propylene glycol (PG) and glycerol (G) vehicle. The vehicle (0 mg/ml nicotine) supported robust VSA, indicating the reinforcing effects of PG/G vapor. 3 mg/ml nicotine did not support VSA, while both 6 and 12 mg/ml nicotine concentrations produced significant reinforcement, with 6 mg/ml yielding the most stable responding. The 6 mg/ml concentration was selected for subsequent comparisons with vanilla-flavored e-liquids. Vanilla flavor (0 mg/ml nicotine) led to maintained VSA behavior, confirming its reinforcing effects. However, the combination of vanilla and nicotine (6 mg/ml) did not alter nicotine intake or withdrawal severity, as assessed by mecamylamine-precipitated somatic signs. Blood nicotine and cotinine levels were similar between nicotine and vanilla + nicotine conditions, indicating that vanilla flavor did not affect systemic nicotine metabolism. Additionally, the PG/G vehicle induced significant somatic signs, suggesting that vapor exposure itself, independent of nicotine, contributes to these physiological responses. These findings provide critical insights into the reinforcing and physiological effects of both nicotine and non-nicotine constituents in e-cigarette aerosols, underscoring the need for future studies and regulatory strategies that consider the abuse liability of flavors and solvents, such as PG/G, particularly among adolescents. Significance StatementFlavored electronic nicotine delivery systems raise concern for promoting nicotine use in youth. Using a rat vapor self-administration model, we show nicotine produces concentration-dependent reinforcement, while vanilla flavor is reinforcing but does not enhance nicotine intake or withdrawal.

pharmacology and toxicology↗